Literature DB >> 11860702

Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes.

Shin-Ichi Muramatsu1, Ken-Ichi Fujimoto, Kunihiko Ikeguchi, Nami Shizuma, Katsuyoshi Kawasaki, Fumiko Ono, Yang Shen, Lijun Wang, Hiroaki Mizukami, Akihiro Kume, Masaru Matsumura, Ikuko Nagatsu, Fumi Urano, Hiroshi Ichinose, Toshiharu Nagatsu, Keiji Terao, Imaharu Nakano, Keiya Ozawa.   

Abstract

One potential strategy for gene therapy of Parkinson's disease (PD) is the local production of dopamine (DA) in the striatum induced by restoring DA-synthesizing enzymes. In addition to tyrosine hydroxylase (TH) and aromatic-L-amino-acid decarboxylase (AADC), GTP cyclohydrolase I (GCH) is necessary for efficient DA production. Using adeno-associated virus (AAV) vectors, we previously demonstrated that expression of these three enzymes in the striatum resulted in long-term behavioral recovery in rat models of PD. We here extend the preclinical exploration to primate models of PD. Mixtures of three separate AAV vectors expressing TH, AADC, and GCH, respectively, were stereotaxically injected into the unilateral putamen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. Coexpression of the enzymes in the unilateral putamen resulted in remarkable improvement in manual dexterity on the contralateral to the AAV-TH/-AADC/-GCH-injected side. Behavioral recovery persisted during the observation period (four monkeys: 48 days, 65 days, 50 days, and >10 months, each). TH-immunoreactive (TH-IR), AADC-IR, and GCH-IR cells were present in a large region of the putamen. Microdialysis demonstrated that concentrations of DA in the AAV-TH/-AADC/-GCH-injected putamen were increased compared with the control side. Our results show that AAV vectors efficiently introduce DA-synthesizing enzyme genes into the striatum of primates with restoration of motor functions. This triple transduction method may offer a potential therapeutic strategy for PD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11860702     DOI: 10.1089/10430340252792486

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  37 in total

Review 1.  Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders.

Authors:  Pedro R Lowenstein; Donata Suwelack; Jinwei Hu; Xianpeng Yuan; Maximiliano Jimenez-Dalmaroni; Shyam Goverdhana; Maria G Castro
Journal:  Int Rev Neurobiol       Date:  2003       Impact factor: 3.230

2.  Dual-gene, dual-cell type therapy against an excitotoxic insult by bolstering neuroenergetics.

Authors:  Tonya M Bliss; Miranda Ip; Elise Cheng; Masabumi Minami; Luc Pellerin; Pierre Magistretti; Robert M Sapolsky
Journal:  J Neurosci       Date:  2004-07-07       Impact factor: 6.167

Review 3.  Parkinson's disease: gene therapies.

Authors:  Philippe G Coune; Bernard L Schneider; Patrick Aebischer
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

Review 4.  Viral vector-based tools advance knowledge of basal ganglia anatomy and physiology.

Authors:  Rachel J Sizemore; Sonja Seeger-Armbruster; Stephanie M Hughes; Louise C Parr-Brownlie
Journal:  J Neurophysiol       Date:  2016-02-17       Impact factor: 2.714

Review 5.  Human gene therapy and imaging in neurological diseases.

Authors:  Andreas H Jacobs; Alexandra Winkler; Maria G Castro; Pedro Lowenstein
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

Review 6.  Adeno-associated virus vectors: potential applications for cancer gene therapy.

Authors:  Chengwen Li; Dawn E Bowles; Terry van Dyke; Richard Jude Samulski
Journal:  Cancer Gene Ther       Date:  2005-12       Impact factor: 5.987

Review 7.  Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions.

Authors:  Pedro R Lowenstein; Ronald J Mandel; Wei-Dong Xiong; Kurt Kroeger; Maria G Castro
Journal:  Curr Gene Ther       Date:  2007-10       Impact factor: 4.391

Review 8.  The pharmacology of regenerative medicine.

Authors:  George J Christ; Justin M Saul; Mark E Furth; Karl-Erik Andersson
Journal:  Pharmacol Rev       Date:  2013-07-01       Impact factor: 25.468

9.  Parkinson disease: Another player in gene therapy for Parkinson disease.

Authors:  Michael G Kaplitt
Journal:  Nat Rev Neurol       Date:  2010-01       Impact factor: 42.937

Review 10.  Tyrosine hydroxylase (TH), its cofactor tetrahydrobiopterin (BH4), other catecholamine-related enzymes, and their human genes in relation to the drug and gene therapies of Parkinson's disease (PD): historical overview and future prospects.

Authors:  Toshiharu Nagatsu; Ikuko Nagatsu
Journal:  J Neural Transm (Vienna)       Date:  2016-08-04       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.